ICAM1 and Stroke: The community‐based Austrian Stroke Prevention Study found that ICAM‐1 was associated with age‐ and gender‐adjusted WMH lesion progression at both 3 and 6 years (3‐year OR, 1.007; 95% CI, 1.002–1.012; p = 0.004; and 6‐year OR, 1.004; 95% CI, 1.000–1.009 per ng/ml; p = 0.057).